SAO PAULO, BRAZIL - A new HIV prevention drug, lenacapavir, is being called a major breakthrough. The WHO has released new ...

Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

Globally, an estimated 4,000 adolescent girls and young women become infected with HIV each week, with sub-Saharan Africa accounting for more than 60% of these new infections, according to the World ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.Presented ...

A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Lenacapavir, new twice-yearly HIV injection, raises hope for pill-weary patients. Discordant couples, sex workers hail ‘game ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...

The World Health Organization has suggested global release of lenacapavir, a twice-yearly injectable medication, as a powerful HIV infection-fighting medication. The historic suggestion was made ...